6-sulfatoxymelatonin has been researched along with Down Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corrales, A; Flórez, J; García, E; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sanchez-Barceló, EJ; Vidal, V | 1 |
| Barlow-Walden, L; Clayton, RJ; Heiden, SM; Poeggeler, B; Reiter, RJ | 1 |
2 other study(ies) available for 6-sulfatoxymelatonin and Down Syndrome
| Article | Year |
|---|---|
Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome.
Topics: Administration, Oral; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Down Syndrome; Drug Administration Schedule; Female; Hippocampus; Male; Maze Learning; Melatonin; Mice; Nerve Degeneration | 2013 |
Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects.
Topics: Adolescent; Adult; Child; Child, Preschool; Circadian Rhythm; Darkness; Down Syndrome; Female; Humans; Light; Male; Melatonin; Middle Aged | 1996 |